Northwind Tadalafil 20mg Tablets Recall: CGMP Deviations
Northwind Pharmaceuticals recalls 20mg Tadalafil tablets due to manufacturing quality issues. Affected lots expire by November 2023. Consumers should check product labels for specific lot numbers and expiration dates.
Lower-risk recall
CGMP Deviations
Contact the company
What happened, in plain English
Northwind Pharmaceuticals is recalling 20mg Tadalafil tablets that were repackaged by their company. The recall is due to CGMP (Current Good Manufacturing Practice) deviations, which means the product may not meet safety standards. This recall affects people who have these specific bottle sizes and lot numbers. Read more at govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations.
Source Summary by GovInfoNow · govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations · Updated August 17, 2026 · FDA enforcement record: FDA #D-0553-2023
Cite this page
“Northwind Tadalafil 20mg Tablets Recall: CGMP Deviations.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations. Based on FDA recall #D-0553-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0553-2023%22&limit=1).
Why it’s dangerous
CGMP deviations refer to failures in the manufacturing process that could affect the product's safety and quality. These deviations mean the tablets might not meet the required standards for safe use, but the specific risk is not described as causing serious injury in normal use.
Who’s affected
People who have the 6-count or 15-count bottles of Tadalafil Tablets, USP 20mg with the listed lot numbers and expiration dates are affected. Those who use prescription medications for erectile dysfunction are most at risk.
How to tell if you have this one
Check the product label for the lot number and expiration date. The affected products are 6-count or 15-count bottles with lot numbers F113892001-F113892203 and expiration dates up to November 2023.
- Brand
Northwind Pharmaceuticals- Category
Drug
All 7 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Ongoing- Distribution
Nationwide with the United States
| Recall number | Product, codes & lots | Quantity | NDC |
|---|---|---|---|
| D-0548-2023 | Atorvastatin Calcium Tablets, USP, 10 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-946-52; Lot # F117192201, Exp. Date 4/30/2023 | 99 bottles | 51655-946-52 |
| D-0549-2023 | BusPIRone Hydrochloride Tablets USP, 7.5 mg, 30-count bottles, Rx Only, Repackaged By: NOrthwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-511-52; Lot#: F117312201, Exp. Date 06/30/2024 | 6 bottles | 51655-511-52 |
| D-0550-2023 | Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52; Lot#: F107752201, Exp. Date 05/31/2024 | 33 bottles | 51655-109-52 |
| D-0551-2023 | Glimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDC 51655-383-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F106252201, Exp. Date 09/30/2024; F106252301, F106252303, Exp. Date 5/31/2025; F106252304, Exp. Date 07/31/2025 b) Lot #: F106252302, Exp. Date 07/31/2025 | a) 230 bottles; b) 22 bottles | 51655-383-26, 51655-383-52 |
| D-0552-2023 | Glimepiride Tablets, USP 4mg, packaged in a) 30-count bottles (NDC 51655-120-52), and b) 90-count bottles (NDC 51655-120-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F105692201, Exp. Date 09/30/2024; F105692203, Exp. Date 02/28/2025 b) Lot #: F105692202, Exp. Date 02/28/2025 | a) 198 bottles; b) 22 bottles | 51655-120-52, 51655-120-26 |
| D-0553-2023 | Tadalafil Tablets, USP 20 mg, packaged in a) 6-count bottles (NDC 51655-473-87), and b) 15-count bottles (NDC 51655-473-54), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F113892002, Exp. Date 08/31/2023; F113892201, Exp. Date 11/30/2023 b) Lot #: F113892001, Exp. Date 08/31/2023; F113892202, Exp. Date 11/30/2023; F113892203, Exp. Date 12/31/2023 | a)164 bottles; b) 198 bottles | 51655-473-54, 51655-473-87 |
| D-0554-2023 | Tadalafil Tablets, USP 5 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-487-52; Lot #: F114302001, Exp. Date 05/31/2023 | 23 bottles | 51655-487-52 |
What to do — step by step
Check Product Label
Look for the lot number and expiration date on the bottle to determine if it is affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide with the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 48 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0553-2023 (March 16, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0553-2023 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.